Search Results

Ascletis Pharma Inc. announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.

Corbus Pharmaceuticals Holdings, Inc., announced , that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002, A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate, has been presented at American Society of Clinical Oncology Annual Conference by Dr. Jian Zhang, Chief Physician, Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today XERAVA® (eravacycline) has been successfully launched in China with its first prescription issued at Huashan Hospital affiliated to Fudan University.

North America Frac Sand, Inc. dba Voycare, a telemedicine service provider and Chinese language digital health platform exclusively dedicated to women’s health, is pleased to welcome Xuan Zhou of Fudan University to its Board of Directors.